Invesco Biotechnology & Genome ETF Rating $98.72 +0.04 (+0.04%) As of 09/3/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy 2.66Holdings in PBE have an aggregate rating of Moderate Buy based on 448 analyst ratings issued in the past year covering 25 companies (90.3% of the portfolio).PBE Aggregate Price Target$98.72High Prediction$98.72Average Prediction$98.72Low Prediction$98.72Holdings in PBE have an aggregate price target of $98.72 and a range of $98.72 to $98.72 covering 25 companies (90.3% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy17 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 PBE Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.44%REGNRegeneron Pharmaceuticals$843.47-1.0%4.0657 of 5 stars2.58$800.36 -5.1%24Trending NewsInsider Trade5.36%AMGNAmgen$444.12+0.3%4.1857 of 5 stars2.40$380.43 -14.3%30Positive NewsAnalyst Revision5.23%VRTXVertex Pharmaceuticals$557.96+0.2%3.4539 of 5 stars2.96$569.52 2.1%23Positive NewsAnalyst Forecast5.19%CDNACareDx$49.86+0.5%3.5154 of 5 stars2.63$51.20 2.7%8Positive NewsAnalyst Forecast4.76%RPRXRoyalty Pharma$63.88+1.2%3.7366 of 5 stars3.00$60.86 -4.7%84.69%BIIBBiogen$224.51+0.8%3.3889 of 5 stars2.58$228.50 1.8%33Trending NewsAnalyst Forecast4.40%GILDGilead Sciences$151.22+1.1%3.7082 of 5 stars2.87$158.04 4.5%30Trending NewsAnalyst UpgradeInsider TradeAnalyst Revision3.83%UTHRUnited Therapeutics$490.24-0.4%4.7351 of 5 stars2.85$646.00 31.8%13Trending NewsInsider Trade3.59%PTGXProtagonist Therapeutics$148.80+1.9%1.5329 of 5 stars2.89$147.13 -1.1%18Trending NewsAnalyst ForecastAnalyst Revision3.56%TECHBio-Techne$72.45+0.2%3.4419 of 5 stars2.12$68.92 -4.9%17Positive News3.50%HALOHalozyme Therapeutics$110.76+1.0%3.7885 of 5 stars2.62$91.20 -17.7%13Trending NewsAnalyst UpgradeAnalyst Revision3.40%RGENRepligen$169.61-1.9%3.2455 of 5 stars3.00$166.43 -1.9%18Positive News3.28%ALNYAlnylam Pharmaceuticals$264.50-1.1%4.5956 of 5 stars2.88$386.14 46.0%25Positive NewsAnalyst Forecast3.27%ACADACADIA Pharmaceuticals$27.86-3.7%4.8259 of 5 stars2.78$34.36 23.3%18Positive News3.14%BMRNBioMarin Pharmaceutical$66.43-0.8%4.8882 of 5 stars2.74$89.17 34.2%23Analyst Forecast3.14%ILMNIllumina$221.66+3.9%2.5095 of 5 stars2.39$191.31 -13.7%18Positive NewsAnalyst Downgrade3.02%VCELVericel$40.47-1.0%3.8908 of 5 stars2.57$58.40 44.3%7Positive News2.96%BCRXBioCryst Pharmaceuticals$10.09-0.8%3.0526 of 5 stars2.67$20.60 104.2%12Positive News2.94%INCYIncyte$128.00-0.6%3.6102 of 5 stars2.56$123.10 -3.8%25Positive NewsAnalyst Forecast2.86%QGENQiagen$43.80-0.9%2.4529 of 5 stars2.43$43.93 0.3%142.78%OMEROmeros$19.11+1.3%4.0554 of 5 stars2.67$38.00 98.8%6Insider Trade2.61%SRPTSarepta Therapeutics$22.99-0.9%2.4136 of 5 stars2.20$25.06 9.0%20Positive News2.54%PTCTPTC Therapeutics$71.40-0.5%3.7425 of 5 stars2.64$98.55 38.0%14Positive NewsAnalyst Upgrade2.39%VCYTVeracyte$44.67-0.5%4.3726 of 5 stars2.82$54.33 21.6%11Positive News2.38%EXELExelixis$59.13+1.0%2.9002 of 5 stars2.35$50.07 -15.3%20Analyst Upgrade This page (NYSEARCA:PBE) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBE Stock Alerts